Equities

Bio-Techne Corp

Bio-Techne Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)74.39
  • Today's Change3.11 / 4.36%
  • Shares traded1.17m
  • 1 Year change+16.22%
  • Beta1.2578
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy5
Outperform6
Hold4
Sell0
Strong Sell0

Share price forecast in USD

The 13 analysts offering 12 month price targets for BIO-TECHNE Corp have a median target of 85.00, with a high estimate of 95.00 and a low estimate of 75.00. The median estimate represents a 19.25% increase from the last price of 71.28.
High33.3%95.00
Med19.2%85.00
Low5.2%75.00

Dividends in USD

In 2024, Bio-Techne Corp reported a dividend of 0.32 USD, equaling last years dividend. The 4 analysts covering the company expect dividends of 0.32 USD for the upcoming fiscal year, maintaining dividends from this year.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in USD

On Oct 30, 2024, BIO-TECHNE Corp reported 1st quarter 2025 earnings of 0.42 per share. This result exceeded the 0.38 consensus of the 13 analysts covering the company and exceeded last year's 1st quarter results by 2.44%.
The next earnings announcement is expected on Jan 30, 2025.
Average growth rate+1.34%
BIO-TECHNE Corp reported annual 2024 earnings of 1.77 per share on Aug 07, 2024.
Average growth rate+13.79%
More ▼

Revenue history & estimates in USD

Bio-Techne Corporation had 1st quarter 2025 revenues of 289.46m. This bettered the 280.26m consensus of the 13 analysts covering the company. This was 4.52% above the prior year's 1st quarter results.
Average growth rate+1.30%
Bio-Techne Corporation had revenues for the full year 2024 of 1.16bn. This was 1.97% above the prior year's results.
Average growth rate+12.39%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.